

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Review Proposal Project

NICE Technology Appraisal TA306; Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma

Stakeholder list

Consultees

Company/sponsor

- CTI BioPharma
- Servier Laboratories Ltd

Patient/carer groups

- African Caribbean Leukaemia Trust (ACLT)
- Anthony Nolan
- Black Health Agency
- Cancer Black Care
- Cancer Equality
- Cancer 52
- Helen Rollason Cancer Charity
- Independent Cancer Patients' Voice
- Leukaemia Cancer Society
- Leukaemia CARE
- Lymphoma Association
- Macmillan Cancer Support
- Maggie's Centres
- Marie Curie
- South Asian Health Foundation
- Specialised Healthcare Alliance
- Sue Ryder
- Tenovus Cancer Care
- Together for Short Lives

Professional groups

- Association of Cancer Physicians
- British Committee for Standards in Haematology
- British Geriatrics Society
- British Institute of Radiology
- British Psychosocial Oncology Society
- British Society for Haematology
- British Transplantation Society
- Cancer Research UK
- ESPRIT
- NHS Blood and Transplant
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Pathologists
- Royal College of Physicians
- Royal College of Radiologists
- Royal Pharmaceutical Society
- Royal Society of Medicine
- Society and College of Radiographers
- United Kingdom Clinical Pharmacy Association
- United Kingdom Oncology Nursing Society

Others

- Department of Health and Social Care
- NHS England
- NHS Nottingham West CCG
- NHS Tameside and Glossop CCG
- Welsh Government

Commentators

General commentators

- All Wales Therapeutics and Toxicology Centre
- Allied Health Professionals Federation

- Board of Community Health Councils in Wales
- British National Formulary
- Care Quality Commission
- Department of Health, Social Services and Public Safety for Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- National Association of Primary Care
- National Pharmacy Association
- NHS Alliance
- NHS Confederation
- Scottish Medicines Consortium
- Welsh Health Specialised Services Committee

Comparators

- Accord (etoposide, gemcitabine, mitoxantrone, oxaliplatin)
- Actavis UK (vinorelbine ditartrate, oxaliplatin, gemcitabine)
- Allergan (etoposide, gemcitabine, oxaliplatin, vinorelbine)
- Baxter Healthcare (mitoxantrone hydrochloride, ifosfamide)
- Bristol-Myer Squibb Pharmaceuticals (etoposide)
- Hospira UK (gemcitabine, vinorelbine ditartrate, oxaliplatin, mitoxantrone hydrochloride, etoposide)
- Lilly UK (gemcitabine)
- Medac UK (gemcitabine, vinorelbine ditartrate, oxaliplatin, etoposide)
- Pierre Fabre (vinorelbine ditartrate)
- Sun Pharmaceuticals UK (gemcitabine)

Relevant research groups

- Cochrane Haematological Malignancies Group
- Institute of Cancer Research
- Leuka
- Leukaemia Busters
- Lymphoma Research Trust

- MRC Clinical Trials Unit
- National Cancer Research Institute
- National Cancer Research Network
- National Institute for Health Research

Associated Public Health groups

- Public Health England
- Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.